Medtronic Launches the Entrust(TM) Delivery System in the United States
August 05 2015 - 03:07PM
New System
Provides an Easy to Use, Accurate and Controlled, One-Handed Stent
Delivery System When Treating Patients with Peripheral Arterial
Disease
DUBLIN - August 5, 2015 - Medtronic plc
(NYSE: MDT) today announced the launch of its Entrust(TM) delivery
system in the United States. The new Entrust delivery system
enables physicians to place Medtronic's EverFlex(TM) self-expanding
peripheral stent, while maintaining a low profile and providing the
ease of a one-handed device.
"The Entrust delivery system allows me to
confidently deliver the EverFlex stent with control and ease,
ensuring precise placement of the stent even in difficult, complex
or hard to reach lesions," said Dr. George Meier, chief of Vascular
Surgery, University of Cincinnati Medical Center.
The Entrust delivery system deploys the EverFlex
stent to re-open narrowed (stenotic) regions of the superficial
femoral and proximal popliteal arteries that supply blood to the
legs. Narrowing of these arteries is associated with a condition
known as peripheral arterial disease (PAD), where plaque builds
along lining of the arteries, blocking blood flow to the legs.
"The Entrust delivery system is a great example of
how industry and physicians can partner to deliver game-changing
technology," said Luke Marone, M.D., chief Cardiovascular Surgery,
UPMC Passavant Hospital, director of Peripheral Intervention UPMC
HVI. "The low profile, long catheter option, and one-handed,
triaxial delivery system put the Entrust delivery system in a class
of its own when it comes to peripheral vascular stents."
The Entrust delivery system provides control and
precision with its 5 F triaxial delivery system and its distinctive
combination of features, including 0.035" guidewire compatibility,
longer catheter lengths, and a broad stent matrix. The Entrust
delivery system uses the EverFlex stent, which has been clinically
proven to be safe and effective in treating long, complex and
highly calcified lesions.
"Based on physician feedback and procedural
observation, we developed an easy to use one-handed delivery system
to increase the stent delivery options in our portfolio," said
Brian Verrier, vice president and general manager of Peripheral
Vascular, a business in Medtronic's Aortic and Peripheral Vascular
division. "Both the Entrust delivery system and the EverFlex(TM)
Stent with the pin-pull delivery system provide enhanced choice and
treatment solutions for peripheral arterial disease."
In collaboration with leading clinicians,
researchers and scientists, Medtronic offers the broadest range of
innovative medical technology for the interventional and surgical
treatment of cardiovascular diseases and cardiac arrhythmias. The
company strives to offer products and services that deliver
clinical and economic value to healthcare consumers and providers
worldwide.
ABOUT MEDTRONIC
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is the global leader in medical technology -- alleviating
pain, restoring health and extending life for millions of people
around the world.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
- end -
Contacts:
Krystin Hayward
Public Relations
+1-508-261-6512
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
HUG#1943576
Medtronic (NYSE:MDT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2023 to Mar 2024